Table 3.
Clinical Commissioning Group (CCG)-level results of between-effects linear panel regression, showing the differences in each outcome, before each feature was launched, between CCG pages that were subsequently viewed on OpenPrescribing.net at various levels and those that were not. For the measure scores, higher is worse.
| Outcome/Number of views | CCGs, n (%) | Mean (SD) | Change | 95% CI | |||||
| Mean measure score (%) | |||||||||
|
|
0 | 0 (0) | N/Aa | N/A | N/A | ||||
|
|
32-135 | 69 (33.5) | 50.6 (8.2) | Reference | N/A | ||||
|
|
139-228 | 70 (34.0) | 50.4 (7.5) | −0.20 | −2.93 to .52 | ||||
|
|
231-2219 | 67 (32.5) | 48.9 (8.7) | −1.74 | −4.50 to 1.01 | ||||
| Price per unit (£ per 1000 patients) | |||||||||
|
|
0 | 40 (19.3) | 365.67 (130.69) | Reference | N/A | ||||
|
|
1-3 | 66 (31.9) | 366.31 (154.46) | 0.64 | −61.16 to 62.43 | ||||
|
|
4-9 | 47 (22.7) | 416.62 (186.29) | 50.95 | −15.40 to 117.29 | ||||
|
|
10-137 | 54 (26.1) | 444.80 (169.25) | 79.12 | 14.79 to 143.46 | ||||
| Low-priority measures (£ per 1000 patients) | |||||||||
|
|
0 | 55 (26.6) | 198.19 (52.31) | Reference | N/A | ||||
|
|
1 | 57 (27.5) | 200.15 (59.52) | 1.96 | −20.40 to 24.32 | ||||
|
|
2-4 | 47 (22.7) | 193.84 (55.02) | −4.36 | −27.85 to 19.14 | ||||
|
|
5-52 | 48 (23.2) | 196.76 (75.82) | −1.44 | −24.80 to 21.93 | ||||
aN/A: not applicable.